Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18387460 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL20599053 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL18387513 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL16764762 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL16764759 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL9932807 | 1.00 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL13167071 | 0.88 | NR1H2 (0.46) | NR1H2USP2SMN1; SMN2RECQLHPGD | |
| SCHEMBL16765553 | 0.85 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL31309202 | 0.85 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL16765554 | 0.85 | NR1H2 (0.43) | NR1H2CHRM2CHRM1CHRM3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | disclosed |
| US-10703756-B2 | Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof | PFIZER INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190002466-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL, PYRROLO[2,3-B]PYRIDINYL ACRYLAMIDES AND EPOXIDES THEREOF | PFIZER INC. (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002466-A1 | PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL, PYRROLO[2,3-B]PYRIDINYL ACRYLAMIDES AND EPOXIDES THEREOF | JAK2, JAK3, JAK1 | NR1H2 4812/4885CHRM2 4081/4885CHRM1 4289/4885 |
| US-10703756-B2 | Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof | JAK2, JAK3, JAK1 | NR1H2 4812/4885CHRM2 4081/4885CHRM1 4289/4885 |
| US-20240150362-A1 | Substituted Pyrrolotriazines | USP7, UBA7, USP5 | NR1H2 2644/4885CHRM2 4811/4885CHRM1 4799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.